faculty

Publications

Plasma Apolipoprotein-AIV Downregulated in Patients with Major Depressive Disorder having Suicidal Ideation Compared to those without Suicidal Ideation.

Groups and Associations Boby Matheworcid, Krishnamachari Srinivasan, Johnson Pradeep, Tinku Thomas and Amit Kumar Mandal*
Current Proteomics 2022

Abstract

Background: Identification of a peripheral biological marker might aid in identifying patients at high risk of attempting suicide and might help in effective early intervention.

Objective: In the present study, we extend the findings of our previous multidimensional proteomics study by examining the levels of plasma Apolipoprotein-AIV in patients diagnosed with major depression with and without suicidal ideation compared to age and gender-matched controls.

Methods: Using the mass spectrometry platform, we quantified the levels of plasma Apolipoprotein- AIV in patients with major depressive disorder with and without suicidal ideation compared to matched controls with isotope-labelled peptides-based quantitative proteomics approach.

Results: The targeted quantitative proteomics approach with isotope-labelled peptides showed that plasma Apolipoprotein-AIV was significantly downregulated in depressed patients having suicidal ideation 1.45 (CI:1.11-1.90) compared to those without suicidal ideation 0.88 (CI:0.77-1.003).

Conclusion: These findings extend our earlier observation of downregulation of plasma Apolipoprotein- AIV in patients with suicidal attempts to depressed patients with suicidal ideation. The consistent downregulation of plasma Apolipoprotein-AIV observed in both the proteomics studies suggests Apolipoprotein-AIV might be a plasma-based biomarker for suicidal behavior.